15 completed, 4 recruiting, 1 not yet recruiting, 1 unknown. 22 Phase 2, 6 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 22 | Completed 15, Recruiting 4, Not yet recruiting 1, Unknown 1, Withdrawn 1 |
| Phase 1 | 6 | Completed 4, Recruiting 2 |
| Phase 3 | 1 | Completed 1 |
Follow Olfactory Nerve Diseases: new trials by email Literature Review of Olfactory Nerve Diseases trials Research Report on Olfactory Nerve Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 2 Study Of Zanzalintinib For Patients With Recurrent Or Metastatic Olfactory Neuroblastoma Zanzalintinib - Metastatic Olfactory Neuroblastoma | Phase 2 | Not yet recruiting | M.D. Anderson Cancer Center | 16 | 2026-10-01 | 2026-10-05 |
| Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors Tarlatamab, Concurrent Radiation Therapy, Sequential Radiation therapy - Melanoma, Medullary Thyroid Cancer | Phase 1 / Phase 2 | Recruiting | University of Arizona | 30 | 2025-09-08 | 2026-10-06 |
| A Phase II Study of Rivoceranib for Patients With Recurrent or Metastatic Olfactory Neuroblastoma Rivoceranib - Metastatic Olfactory Neuroblastoma, Recurrent Olfactory Neuroblastoma | Phase 2 | Withdrawn | M.D. Anderson Cancer Center | 2024-11-01 | 2025-01-10 | |
| Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed). Olaparib; 177Lu-DOTATATE - Solid Tumor Cancer, Medulloblastoma | Phase 1 / Phase 2 | Recruiting | Fundación de investigación HM | 25 | 2024-09-20 | 2026-06-04 |
| Enasidenib in IDH2-Mutated Malignant Sinonasal and Skull Base Tumors Enasidenib - Metastatic Chondrosarcoma, Locally Advanced Chondrosarcoma | Phase 2 | Recruiting | National Cancer Institute (NCI) | 40 | 2024-03-04 | 2026-11-05 |
| Efficacy and Safety of Induction Chemotherapy for Olfactory Neuroblastoma (ESICON) Gemcitabine+Cisplatin(GP); Cyclophosphamide+Etoposide+Cisplatin(CEP) - Olfactory Neuroblastoma | Phase 2 | Recruiting | Hongmeng Yu | 25 | 2024-03-01 | 2024-02-13 |
| Phase 2 Study of Bintrafusp Alfa in Recurrent/Metastatic Olfactory Neuroblastoma (BARON). Bintrafusp alfa/M7824, Ibuprofen, PET scan - Olfactory Neuroblastoma, Esthesioneuroblastoma | Phase 2 | Completed | National Cancer Institute (NCI) | 11 | 2022-06-21 | 2025-08-08 |
| A Clinical Trial of Endoscopic Surgery Followed by Chemotherapy and Proton Radiation for the Treatment of Tumors in the Sinus and Nasal Passages Cisplatin, Adjuvant Proton Radiotherapy, Endoscopic Resection - Paranasal Sinus Cancer, Nasal Cavity Tumor | Phase 2 | Completed | Memorial Sloan Kettering Cancer Center | 3 | 2017-09-01 | 2025-05-16 |
| 18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy 18F-fludeoxyglucose (18F-FDG), 18F-FPPRGD2 - Adult Giant Cell Glioblastoma, Adult Glioblastoma | Phase 1 / Phase 2 | Completed | Sanjiv Sam Gambhir | 25 | 2013-03-04 | 2019-10-03 |
| External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases indinavir sulfate, ritonavir, radiation therapy - Cancer | Phase 2 | Unknown | Oncology Institute of Southern Switzerland | 60 | 2007-09-01 | 2013-08-12 |
| Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck Cancer bevacizumab, placebo, magnetic resonance imaging - Adult Anaplastic Astrocytoma, Adult Anaplastic Ependymoma | Phase 2 | Completed | National Cancer Institute (NCI) | 11 | 2007-06-01 | 2014-05-09 |
| Gemcitabine and Doxorubicin in Treating Patients With Recurrent or Progressive Head and Neck Cancer doxorubicin hydrochloride, gemcitabine hydrochloride - Head and Neck Cancer | Phase 2 | Completed | Medical University of South Carolina | 18 | 2005-06-01 | 2018-07-12 |
| Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung Cancer erlotinib hydrochloride, cetuximab, bevacizumab - Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Adenoid Cystic Carcinoma of the Oral Cavity | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 66 | 2005-01-01 | 2014-06-11 |
| Oxaliplatin and Capecitabine in Treating Patients With Relapsed or Metastatic Head and Neck Cancer capecitabine, oxaliplatin - Head and Neck Cancer | Phase 2 | Completed | University of Miami | 30 | 2004-02-01 | 2016-12-15 |
| Epirubicin, Carboplatin, and Capecitabine in Treating Patients With Unresectable Locally Advanced, Metastatic, or Recurrent Solid Tumor capecitabine, carboplatin, epirubicin hydrochloride - Esophageal Cancer, Extrahepatic Bile Duct Cancer | Phase 1 / Phase 2 | Completed | National Institutes of Health Clinical Center (CC) | 2001-07-01 | 2012-03-08 | |
| Paclitaxel and Cisplatin Plus Radiation Therapy Followed by Filgrastim in Treating Patients With Recurrent Head and Neck Cancer or Lung Cancer filgrastim, cisplatin, paclitaxel - Head and Neck Cancer, Lung Cancer | Phase 2 | Completed | Fox Chase Cancer Center | 29 | 1999-09-01 | 2013-04-17 |
| Chemotherapy Plus Peripheral Stem Cell Transplant in Treating Patients With Central Nervous System Cancer filgrastim, carmustine, cisplatin - Brain and Central Nervous System Tumors, Head and Neck Cancer | Phase 2 | Completed | Herbert Irving Comprehensive Cancer Center | 30 | 1999-04-01 | 2013-02-04 |
| Docetaxel in Treating Patients With Solid Tumors docetaxel - Bladder Cancer, Breast Cancer | Phase 2 | Completed | Alliance for Clinical Trials in Oncology | 109 | 1998-09-01 | 2016-07-14 |
| High-dose ICE With Amifostine filgrastim, Amifostine, Carboplatin - Bladder Cancer, Brain and Central Nervous System Tumors | Phase 2 | Completed | Dana-Farber Cancer Institute | 24 | 1998-07-01 | 2017-01-20 |
| Vaccine Therapy Plus Biological Therapy in Treating Adults With Metastatic Solid Tumors aldesleukin, ras peptide cancer vaccine, sargramostim - Colorectal Cancer, Endometrial Cancer | Phase 2 | Completed | National Cancer Institute (NCI) | 1997-10-01 | 2013-06-20 |
Showing 20 of 22. Sign in to see all of them.
Esthesioneuroblastoma, Olfactory (22) · Squamous Cell Carcinoma of Head and Neck (12) · Head and Neck Neoplasms (10) · Salivary Gland Neoplasms (10) · Carcinoma, Non-Small-Cell Lung (9) · Colonic Neoplasms (5) · Lung Neoplasms (5) · Urinary Bladder Neoplasms (5) · Brain Neoplasms (4) · Breast Neoplasms (4) · Carcinoma, Renal Cell (4) · Pancreatic Neoplasms (4) · Rectal Neoplasms (4) · Small Cell Lung Carcinoma (4) · Carcinoma, Ovarian Epithelial (3)
Cranial Nerve Diseases (22) · Neoplasms by Histologic Type (22) · Neoplasms, Germ Cell and Embryonal (22) · Neoplasms, Glandular and Epithelial (22) · Neoplasms, Nerve Tissue (22) · Neoplasms, Neuroepithelial (22) · Nervous System Diseases (22) · Neuroectodermal Tumors (22) · Neuroectodermal Tumors, Primitive (22) · Neuroblastoma (21) · Neuroectodermal Tumors, Primitive, Peripheral (21) · Neoplasms (20) · Neoplasms by Site (18) · Carcinoma (15)
Cisplatin (3) · Etoposide (3) · Filgrastim (3) · Radiotherapy (3) · Bevacizumab (2) · Capecitabine (2) · Carboplatin (2) · Docetaxel (2) · Peripheral Blood Stem Cell Transplantation (2) · Amifostine (1) · Carmustine (1) · Cetuximab (1) · Chemotherapy, Adjuvant (1) · Cyclophosphamide (1) · Doxorubicin (1)
National Cancer Institute (NCI) (5) · M.D. Anderson Cancer Center (2) · Memorial Sloan Kettering Cancer Center (2) · University of Miami (2) · Alliance for Clinical Trials in Oncology (1) · Dana-Farber Cancer Institute (1) · Fox Chase Cancer Center (1) · Fundación de investigación HM (1) · Herbert Irving Comprehensive Cancer Center (1) · Hongmeng Yu (1) · Medical University of South Carolina (1) · National Institutes of Health Clinical Center (CC) (1) · Oncology Institute of Southern Switzerland (1) · Sanjiv Sam Gambhir (1) · University of Arizona (1)
United States (18) · Canada (1) · China (1) · Puerto Rico (1) · Spain (1) · Switzerland (1)
Charalampos Floudas, M.D. (2) · Alain Mita (1) · Arnold M. Markoe, MD, ScD (1) · Barry L. Gause, MD (1) · Brian P. Monahan, MD, FACP (1) · Charles Hsu, MD (1) · Charles S. Hesdorffer, MD (1) · Corey J. Langer, MD (1) · Eva Szabo, MD (1) · Hongmeng Yu, Prof. (1) · Ilja Ciernik, MD (1) · Lionel Lewis, MD (1) · Luana Guimaraes De Sousa, MD (1) · Luana Sousa, MD (1) · Luis E. Raez, MD, FACP (1)
PMID 17545536, PMID 21791630, PMID 25965900, PMID 26062933, PMID 26611425, PMID 30850872, PMID 39500789, PMID 42307670
N01CM62202 (1), P30CA006516 (1), P30CA006927 (1), P30CA016672 (1), P30CA054174 (1), U01CA069853 (1), U10CA031946 (1)